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Abstract
Protection against P. berghei malaria can successfully be induced in mice by immunization with both radiation attenuated
sporozoites (RAS) arresting early during liver stage development, or sporozoites combined with chloroquine
chemoprophylaxis (CPS), resulting in complete intra-hepatic parasite development before killing of blood-stages by
chloroquine takes place. We assessed the longevity of protective cellular immune responses by RAS and CPS P. berghei
immunization of C57BL/6j mice. Strong effector and memory (TEM) CD8+ T cell responses were induced predominantly in
the liver of both RAS and CPS immunized mice while CD4+ T cells with memory phenotype remained at base line levels.
Compared to unprotected naı¨ve mice, we found high sporozoite-specific IFNc ex vivo responses that associated with
induced levels of in vivo CD8+ TEM cells in the liver but not spleen. Long term evaluation over a period of 9 months showed
a decline of malaria-specific IFNc responses in RAS and CPS mice that significantly correlated with loss of protection
(r2 = 0.60, p,0.0001). The reducing IFNc response by hepatic memory CD8+ T cells could be boosted by re-exposure to wild-
type sporozoites. Our data show that sustainable protection against malaria associates with distinct intra-hepatic immune
responses characterized by strong IFNc producing CD8+ memory T cells.
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Introduction
Malaria is transmitted to the host through bites of Plasmodium
infected mosquitoes that inject sporozoites into the skin. These
sporozoites travel to the liver for further development and released
as blood-stage parasites that are responsible for clinical malaria
[1]. A number of whole-parasite models including sporozoites or
blood-stage parasites are currently in use to study mechanisms of
protective immunity [2,3,4]. Immunization by whole sporozoites
currently makes use of three main approaches: genetically
attenuated sporozoites (GAS); radiation attenuated sporozoites
(RAS) or sporozoites under chemoprophylactic cover – with for
instance chloroquine (CPS). RAS arrest early in the liver stage
development [5], disrupting the normal cycle of the parasite while
allowing the host to develop an immune response able to
overcome disease upon subsequent challenge. In the CPS
approach, the anti-malarial drug chloroquine (CQ) rapidly clears
parasites from the bloodstream without affecting the liver stages
[6] while allowing the host to mount a fully protective immune
response.
Sterile protection against malaria by whole sporozoites is
thought to be mediated by hepatic CD8+ T cell responses. The
expansion of CD8+ T cells with memory phenotype, identified by
the high expression of CD44, as well as high production of IFNc
have been shown to associate with protection by RAS [7,8,9,10].
Moreover, depletion of CD8+ T cells prior to challenge have
been shown to nearly entirely abrogate complete protection [11].
Regarding CPS, limited data so far suggest a protective role for
both CD4+ and CD8+ T cells as well as IFNc but not IL-6, IL-12
or TNF [6]. On top of encouraging high protection levels
observed in mice studies [2,6,12,13], RAS and CPS models have
also been shown to induce complete protection in men [2,14].
Better understanding of the dynamics of liver-mediated CD8+ T
cell responses and evaluation on long term are essential
characteristics to explore in the context of long-lived protection
by a pre-erythrocytic whole parasite malaria vaccine. In the
present study, we evaluate the longevity of components essential
for protection by RAS or CPS immunization with P. berghei
sporozoites.
Results
Protection associates with intra-hepatic effector
(memory) CD8+ T cell responses
Groups of C57BL/6j mice were immunized with either a high
(50 K/20 K/20 K) or low (10 K/10 K/10 K) dose of P. berghei
ANKA sporozoites (Pbspz) according to RAS or CPS protocols
(Fig. 1). Induced memory responses were analyzed in PBMC,
hepatic mononuclear cell (HMC) and splenocytes by flow
cytometry at day 40 (26 days after the last immunization).
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Overall, CD4+CD44hi or CD8+CD44hi T cell responses in
PBMC, HMC and splenocytes were similar for both tested
regimens (Fig. 2a). Both RAS and CPS immunized groups
showed a similar and clear expansion in the proportion of
CD8+CD44hi T cells in liver, primarily due to an up to 4-fold
increase of the CD8+ T cells with effector memory phenotype
(TEM: CD44hiCD62L2) and without obvious alterations in the
central memory (TCM: CD44hiCD62L+) pool (Fig. 2b). In spleen
and blood, the fraction of CD8+CD44hi T cells to the total
CD8+ T cell pool did not change, but there was an up to 2.5 fold
proportional increase of CD8+ TEM cells. Generally, the changes
in CPS-induced CD8+ TEM cells were smaller compared to RAS
immunizations. Post-immunization changes in memory CD4+ T
cell pool were minimal and only observed in HMC of immunized
mice.
Both high (50 K/20 K/20 K) and low (10 K/10 K/10 K)
immunization doses with either RAS or CPS regimes induced
complete protection in 100% of the mice (Table 1). All naı¨ve mice
developed parasitemia as determined by Giemsa-stained smears of
tail blood.
Dynamics of liver CD8+ TEM cells and IFNc response in
RAS and CPS immunized mice
We next studied the effect of challenge infections on the
dynamics of CD4+ and CD8+ TEM cells. Prior to challenge (C-1)
the proportion of CD8+ TEM cells was higher in PBMC, HMC
and splenocytes of RAS-compared to CPS immunized mice
(Fig. 3). There was a gradual significant downward trend in intra-
hepatic CD8+ TEM cells in RAS immunized animals up to 21 days
post-challenge (p = 0.007) while the post-immunization profile
remained stable in CPS immunized mice. Overall, CD8+ but not
CD4+ TEM cells, only from liver but not spleen or peripheral
blood remained significantly higher in immunized versus naı¨ve
mice. Interestingly, CD8+ TEM cells from naı¨ve mice significantly
increased during fatal infection up to day 6 post-challenge
(p = 0.008), most strikingly in the liver but also in spleen and
peripheral blood. All data combined indicate the strongest
memory T cell responses to be generated intra-hepatically.
IFNc responses of CD8+ T cells with memory phenotype
(CD44hi) induced by RAS or CPS immunization was assessed 21
days following challenge at day 41 (C+21). Freshly isolated HMC
and splenocytes were ex vivo stimulated with cryo-conserved P.
berghei sporozoites. CD8+CD44hi T cells of RAS and CPS mice
show similar IFNc responses albeit somewhat higher in the liver
than in the spleen (Fig. 4). Liver and spleen cells from naı¨ve mice
barely show any ex vivo IFNc response to Pbspz while the positive
control stimulation with PMA and ionomycin resulted in
percentage of responding cells similar to immune mice (data not
shown).
Declining IFNc response by liver CD8+ memory T cells
correlates with loss of protection
To evaluate the sustainability of the hepatic CD8+ T cell
responses measured after immunization by RAS and CPS
protocols, levels of CD8+ TEM were assessed 3, 6 or 9 months
following the last immunization by three doses of 10 K
sporozoites. Analysis of the memory pool showed compared to
naı¨ve mice, sustained and significantly high levels of CD8+ T
cells with effector memory phenotype up to 9 months post-
immunization (Fig. 5). In the spleen, composition of the CD8+ T
cell memory pool did not differ between naı¨ve and immunized
mice.
We further explored the differences in antigen exposure of RAS
and CPS protocols (tested by serology) and assessed the longevity
of IFNc response by hepatic CD8+ T cells. While concentrations
of anti-sporozoite specific IgG antibodies were equal in all
immunized mice, only the CPS protocol as expected induced
anti-blood-stage specific IgG antibodies (Fig. 6). Challenge
infection resulted in a further increase of parasite specific IgG
levels while RAS-induced antibodies remained negative for blood-
stages. These data show that antigen exposure to RAS is limited to
pre-erythrocytic stages while CPS immunization induces both pre-
erythrocytic- and blood-stage specific antibodies. At 3 months
post-immunization, IFNc response by hepatic CD8+CD44hi T
cells against sporozoites (Pbspz) or infected red blood cells
(PbiRBC) were significantly increased, with the highest responses
in RAS immunized mice(Fig. 7A). However, a decline in Pbspz
specific IFNc response was observed over a 3 to 9 months post-
immunization period (Fig. 7B). In contrast, non-specific polyclonal
stimulation showed a constant and equally high IFNc response at
all timepoints in all groups. Bloodstage specific IFNc response
showed a similar pattern in the liver while splenocytes failed to
show sporozoite or bloodstage specific IFNc responses distinct
from naı¨ve mice (data not shown).
Long-term protection was evaluated by challenge at 3, 6 or 9
months post immunization. While RAS protocol induced 100%
protection at all time points, CPS-induced protection was reduced
from 100% (t = 3 and 6 months) to 50% (t = 9 months) (Table 2).
Interestingly, decreased sporozoite specific IFNc response by
hepatic CD8+CD44hi T cells significantly correlated with
decreased protection levels observed from 3 to 9 months
(r2 = 0.60, p,0.0001).
Re-exposure boost levels of liver CD8+ TEM cells and IFNc
response
We finally investigated whether decreased liver CD8+ TEM cell
response could be boosted by re-exposure. In protected mice
challenged 3, 6 or 9 months after immunization, levels of liver
CD8+ TEM showed at day 21 after individual challenge infections
a significant increase in proportion of CD8+ TEM (Fig. 8A).
Moreover, sporozoite specific IFNc response by hepatic
CD8+CD44hi T cells was boosted by each challenge infection
(Fig. 8B). Although not strong, there was a significant correlation
between the overall levels of CD8+ TEM+ cells and the sporozoite
Figure 1. Experimental set-up high and low dose immuniza-
tions. C57BL6j mice were immunized intravenously (day 0, day 7 and
day 14) by radiation attenuated sporozoites (RAS) or chloroquine
prophylactic sporozoites (CPS). CPS mice received chloroquine (CQ)
once a day for 24 days starting from the first day of immunization.
Absence of blood-stage parasites was confirmed before challenge at
day 41. Blood, liver and spleen were collected one day before challenge
(C-1 – day 40), six days (C+6 – day 46) and twenty-one days (C+21 – day
62) after challenge (dotted arrows). Protection was assessed by
determination of parasitemia on Giemsa stained thin blood smears
between day 3 to 21 after challenge.
doi:10.1371/journal.pone.0036508.g001
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specific IFNc response before and after challenge (p = 0.007,
r2 = 0.13).
Discussion
The present study highlights the essential role of IFNc
response by liver memory CD8+ T cell for the longevity of
protection against malaria. After both P. berghei RAS and CPS
immunization, similar T cell responses are induced with
increase of predominantly the CD8+ T cell pool with memory
phenotype in liver, and to a lesser extent in spleen and PBMC.
The composition of the CD4+CD44hi T cell pool remains
relatively unaffected. The observed changes after RAS
immunization corroborate data from previous studies showing
clear liver CD8+ TEM cells responses with modest expansion of
spleen cells and PBMC [7,8,9,10]. Initially, both RAS and
CPS protocols are equally efficient in the induction of
complete protection, compliant with an apparent key role of
liver CD8+ TEM cells with IFNc as one of the main actors.
Further long term evaluation of RAS or CPS induced immune
responses and protection clearly shows that up to 9 months
after immunization, malaria specific IFNc response declines
despite sustained high levels of liver CD8+ TEM cells. This
waning IFNc response significantly correlates with loss of
protection observed in CPS mice 9 months after immunization
(r2 = 0.60, p,0.0001). In a previous study by Jobe et al [10], P.
berghei RAS immunization was shown to induce liver IFNc-
secreting CD8+ T cells still measurable at high levels upon re-
challenge 6 months after the first challenge infection. While
these findings are in line with our post-challenge observations,
our pre-challenge data show that in its natural course, CD8+
T-cell mediated protective immune response declines over time
yet remains detectable months after immunization prior to
boost by re-exposure.
Several studies have addressed protection in murine malaria
models with parallel immune responses. Schmidt et al have
shown induced and sustained (up to 5 months) CD8+ memory T
cell response defined by presence of CD8aloCD11ahi T cells in
peripheral blood [15]. High levels of PBMC CD8aloCD11ahi T
cells were however not sufficient to induce protection. Similar
findings were reported by Friesen et al, showing equally high
levels of PBMC CD8aloCD11ahi T cells in mice immunized by P.
berghei RAS or under azythromycin chemoprophylaxis despite
protection levels of 40 and 80% respectively [16]. In spite of
strong indications of induced protective immune responses,
abundant presence of neither CD8aloCD11ahi T cells (as shown
by others) or CD8+ T cells with classical effector memory
phenotype (CD44hiCD62L2) are sufficient to predict protection.
On top of quantitative analysis of CD8+ memory T cell
responses, the present study supports the predictive value of
malaria specific IFNc response for longevity of protective
immunity.
Our findings of a more sustained protective immunity induced
by RAS compared to CPS are somewhat surprising. As shown
by Butler et al., late arresting genetically attenuated P. yoelii
parasites induce a more robust protective immune response in
mice compared to RAS [17]. Furthermore, RAS immunizations
in humans are clearly less efficient than the CPS protocol
[14,18]. This may obviously be related to differences in immune
mechanisms in humans and animal models using adapted
species. In addition, it is difficult to make comparison between
our findings and data from Butler et al. as development of
genetically attenuated parasites differ between P. berghei and
P. yoelii [19].
Finally, encouraging long term protection up to 42 [18] and 122
[20] weeks has been shown in humans immunized by RAS and
CPS protocols respectively. Underlying protective mechanisms of
RAS protection in men show on short term malaria specific IFNc
responses [21]. CPS clinical trials show that protection sustained
for more than two years [14,20] associates with malaria specific
IFNc responses that last for at least 14 months [22]. Therefore,
IFNc, presented as ‘central mediator of protective immune response against
malaria’ [23], does not only point out immediate protection but




C57BL/6j mice (6 to 8 weeks old) were purchased from
Elevage-Janvier (Le Genest Saint Isle, France). Mice were housed
at the Central Animal Facility in Nijmegen and received a
standard diet and water ad libitum. All animal studies and
procedures were approved by the Ethical Committee on Animal
Research of the Radboud University Nijmegen (RU-DEC 2008-
198, 2009-170, 2009-226).
P. berghei (ANKA) sporozoites (Pbspz) were obtained by
dissection of the salivary glands of infected female Anopheles
stephensi mosquitoes 21–29 days after blood meal on infected mice.
To obtain radiation attenuated sporozoites (RAS), infected




RAS 50/20/20 (6103) 10/10 100
RAS 10/10/10 (6103) 20/20 100
CPS 50/20/20 (6103) 5/5 100
CPS 10/10/10 (6103) 10/10 100
Naı¨ve 0/23 0%
aCPS mice received 24-days chloroquine treatment. All immunized mice were
challenged 17 days after CQ treatment.
bCumulative data from three experiments. In two experiments, mice were
challenged by i.v. injection of 10.000 WT sporozoites. In one experiment, mice
were challenged by bites of 5–11 infected mosquitoes. Protection was defined
as negative blood-smears at day 21 after challenge.
doi:10.1371/journal.pone.0036508.t001
Figure 2. Phenotypic analyses CD44hi T-cells. (A) Gating strategy. After lymphocytes gating based on forward-scatter (FSC) and side-scatter
(SSC) properties, CD4+ and CD8+ T cells were selected. Total memory T cells were gated based on high CD44 expression. T cells with effector memory
(TEM) and central memory (TCM) phenotype were identified based on CD62L expression. (B) CD8+CD44hi and CD4+CD44hi T-cell pool at day 40 post-
immunization with high or lose dose. Composition of the CD8+CD44hi and CD4+CD44hi T-cell pool was assessed in the liver (left panel), spleen
(central panel) or PBMC (right panel) of mice immunized by high and low dose of RAS or CPS. Results are from 2 independent experiments (nRAS = 10;
nCPS = 10; nnaı¨ve = 13) and cells from individual mice assayed. Error bars represent standard error of the mean (SEM). * = p,0.05, ** = p,0.005,
*** = p,0.0001.
doi:10.1371/journal.pone.0036508.g002
Long Term Murine Malaria Protective Immunity
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36508
mosquitoes were irradiated at 16,000 rad (Gammacell 1000 137Cs)
prior to dissection.
Immunization schedules, challenge and protection
Mice received three intravenous injections with weekly intervals
of two Pbspz doses: 50.000-20.000-20.000 or 10.000-10.000-
10.000. During CPS immunization, mice received a daily i.p.
injection of 800 mg of chloroquine base starting simultaneously
with the first inoculation up to two weeks after the last sporozoite
inoculation. Chloroquine disphosphate (CQ, Sigma-aldrich) was
diluted in PBS and administered to both immunized and naı¨ve
mice. At the end of the chloroquine treatment and approximately
a day before challenge, absence of parasitemia was confirmed by
examination of Giemsa-stained slides of tail blood.
Absence of blood-stage parasites prior to challenge was
confirmed at the end of the rested phase in all groups. CPS or
RAS immunized and naı¨ve mice were simultaneously challenged
at day 41 or 3 to 9 months after the last immunization by i.v.
injection of 10,000 WT Pbspz. In one experiment, mice were
challenged by bites of 5–11 infected mosquitoes. Presence of
sporozoites in mosquitoes after feeding was confirmed by
examination of the dissected salivary glands.
Parasitized red blood cells were identified by Giemsa-stained
blood smears on other days from day 3–14 and finally on day
21 after challenge. Protection was defined as the absence of
blood-stage parasites by day 21 post-challenge. A schematic
representation of the experimental design is presented in
figure 1.
Serology
Antigen extraction from whole P. berghei sporozoites or infected
red blood cells (iRBC) was performed as described by Bousema et
al [24]. Briefly, parasites were incubated in 25 mM Tris-HCl,
pH 8.0, supplemented with 150 mM NaCl, 1.0% sodium
desoxycholate, and 1 mM phenylmethylsulfonylfluoride. Insoluble
Figure 3. CD4+ and CD8+ TEM cells in response to challenge. Changes in the effector memory CD8+ and CD4+ T-cell compartment from the
liver, spleen and PBMC of mice immunized with low dose of RAS (n = 15) or CPS (n = 12) were evaluated at various time-points around challenge (C-1,
C+6, C+21). Results are from 3 independent experiments (nnaı¨ve = 18) and cells from individual mice assayed. Error bars represent standard error of the
mean (SEM). * = p,0.05, *** = p,0.0001.
doi:10.1371/journal.pone.0036508.g003
Figure 4. IFNc response by liver and spleen CD8+CD44hi T
cells. At day 62, liver and spleen cells collected from immune RAS or
CPS mice were stimulated for 24 hours ex vivo with cryo-conserved
Pbspz. IFNc response was assessed by intracellular cytokine staining
prior to flow-cytometry measurement (2 experiments). The percentage
of IFNc+ lymphocytes upon stimulation with PMA and ionomycin was
similar between RAS (n = 15), CPS (n = 10) and naı¨ve (n = 6) mice in the
liver (6.9%, 5.2%, 5.1%) or spleen (1.33%, 1.65%, 1.1%). * = p,0.05,
** = p,0.001.
doi:10.1371/journal.pone.0036508.g004
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debris were separated by centrifugation (5 minutes, 13.0006g
RT)and overnight coating of Sterilin ELISA plates (International
Medical Products B.V.) was performed with the equivalent of
40.000 iRBC or 4.000 sporozoites per well. After blocking with
5% milk/PBS, plasma samples were incubated for three hours at
room temperature (in 0.1% milk, Tween 20, PBS). Rabbit anti-
mouse IgG HRP (SouthernBiotech, Birmingham, AL USA) was
used for the detection of IgG antibodies to sporozoites or blood-
stage antigens.
Cell preparation
Before and after challenge, mice were euthanized by
isoflurane inhalation after i.v. injection of 50 IU of heparin.
Blood, spleen and liver were collected after perfusion of the liver
with 10 ml of PBS. Cell suspensions of liver and spleen were
made by passage of the organs through a 70-mm nylon cell
strainer (BD Labware). Liver cells were resuspended in 35%
Percoll (GE Healthcare) and centrifuged at 800 g for 20 min.
Liver and spleen erythrocytes were lysed by 5 min incubation on
ice in ACK lysing solution. After erythrocyte lysis, HMC and
splenocytes were resuspended in PRMI 1640 medium. Isolation
of peripheral blood mononuclear cells (PBMC) was performed
using Histopaque-1077 (Sigma-Aldrich) according to the man-
ufacturer’s recommendation.
Memory phenotyping and anti-sporozoite or bloodstage
IFNc response
Five-color staining of PBMC, HMC and splenocytes was
performed using monoclonal antibodies purchased by Biolegend:
Pacific blue-conjugated anti CD3 (17A2), Peridinin Chlorophyll
Protein (PerCP)-conjugated anti CD4 (RM4.5), Alexa fluor 700-
conjugated anti CD8a (53–6.7), fluorescein isothiocyanate (FITC)–
conjugated anti-CD44, allophycocyanin (APC)– or phycoerythrin-
Cy7 (PE-Cy7)-conjugated anti-CD62L (MEL-14). Briefly, 106 cells
were resuspended in cold assay buffer (PBS supplemented with
0.5% bovine serum albumin (Sigma-Aldrich) and incubated for
30 min at 4uC with the monoclonal antibodies. Cells were fixed
with Fix & Perm medium A (Invitrogen) and resuspended in assay
buffer for measurement.
HMC and splenocytes (56105 cells/well) were co-cultured in
complete RPMI 1640 culture medium [25] in presence of cryo-
preserved sporozoites (SPZ - 56104/ml), P. berghei infected red
blood cells (iRBC - 56106/ml), salivary gland preparations from
uninfected mosquitoes or uninfected red blood cells (uRBC -
56106/ml). Cells were stimulated at 37uC/5%CO2 for 24 hours
and Brefeldin A (Sigma) was added during the last four hours
(10 mg/ml final concentration). As positive control, PMA (100 ng/
ml) and Ionomycin (1.25 mg/ml) (Sigma) were added simulta-
neously with Brefeldin A. Cells were harvested after 24-hours in
vitro stimulation and stained with monoclonal antibodies against
Figure 5. CD8+ TEM levels up to 9 months post-immunization. Levels of liver and spleen CD8+ T cells with effector memory (TEM) were
measured at 3, 6 and 9 months after RAS or CPS immunization. Error bars represent standard error of the mean (SEM). * = p,0.05.
doi:10.1371/journal.pone.0036508.g005
Figure 6. Sporozoite and blood-stage specific IgG. Plasma were collected from mice immunized by RAS or CPS before (C-1) and 6 to 21 days
after (C+6; C+21) challenge. Levels of anti-sporozoite or anti-blood-stage IgG antibodies were determined by ELISA (nRAS = 5; nCPS = 5; nnaı¨ve = 9). Error
bars represent standard error of the mean (SEM). ** = p,0.005, *** = p,0.0001.
doi:10.1371/journal.pone.0036508.g006
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CD3, CD4, CD8a and CD44 as indicated above. Fixed cells were
stained with APC-conjugated anti-IFNc with Fix & Perm medium
B (Invitrogen) at 4uC for 30 min.
Flow cytometry and data analysis and statistics
Flow cytometry was performed on a 9-color Cyan ADP
(Beckman Coulter) and data analysis using FlowJo software
(version 9.1; Tree Star). For the analysis of cytokine production,
background response to salivary glands or uRBC was subtracted
Figure 7. Declined specific IFNc response by hepatic CD8+ memory T cells over time. Sporozoite specific IFNc response by hepatic
CD8+CD44hi T cells was measured by intracellular staining at 3 months post-immunization (A) – individual values and median are plotted. Longevity
of the specific (sporozoites) and non-specific (PMA/Ionomycin) IFNc response was further assessed 6 and 9 months after immunization (B) – error bars
represent SEM. * = p,0.05, ** = p,0.001.
doi:10.1371/journal.pone.0036508.g007
Table 2. Long-term RAS and CPSa protection following P. berghei sporozoite challengeb.
Challenge (time post-immunization) No. protected/No. challenged (% protection)
RAS CPS Naive
3 Months 5/5 (100) 5/5 (100) 0/6 (0)
6 Months 5/5 (100) 5/5 (100) 0/3 (0)
9 Months 5/5 (100) 4/8 (50) 0/3 (0)
aCPS mice received 24-days chloroquine treatment. Three of the six naı¨ve mice challenged at t = 3months receive the same chloroquine treatment.
bMice were challenged by i.v. injection of 10.000 WT sporozoites. Protection was defined as negative blood-smears at day 21 after challenge.
doi:10.1371/journal.pone.0036508.t002
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from Pbspz and iRBC responses for each individual mouse. Overall
comparisons between RAS, CPS and naı¨ve groups was performed
by Kruskas-Wallis test and subsequent individual comparisons
were performed by a Dunn’s multiple comparisons test using
PRISM software version 5.0 (Graphpad, San Diego, CA). p,0.05
was considered statistically significant.
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